On September 20, 2022, Darren M. Magot voluntarily resigned from the Board of Directors of Imperalis Holding Corp. Effective immediately upon Mr. Magot's resignation, Douglas Gintz, the Company's Chief Technology Officer, and Marcus Charuvastra, the Company's President, were appointed to serve on the Board. Douglas Gintz has served as Chief Technology Officer since September 6, 2022.

Prior thereto, he served as the Chief Technology Officer of TurnOnGreen Inc., since February 2021. Mr. Gintz has over 30 years of hands-on experience bringing products to market. Specializing in emerging technologies, Mr. Gintz has developed manufacturing compliance systems, DNA reporting engines, medical billing software, e-commerce applications, and retail software for companies ranging from startups to multinational corporations.

Mr. Gintz also currently serves as the Chief Technology Officer and Director of Global Technology Implementation for the Parent since February 2021. Mr. Gintz's previous leadership roles include Chief Executive Officer of Pacific Coders, LLC. from August 2002 to January 2022; Chief Technology Officer of Endocanna Health Inc. from January 2019 to January 2021; Mr. Gintz served at Targeted Medical Pharma Inc., a publicly-traded microcap, as Chief Marketing Officer and Technology Officer from January 2018 to December 2019, and Chief Technology Officer and Chief Information Officer from January 2012 to May 2016.

Marcus Charuvastra as served as our President since September 6, 2022. Prior thereto, he served as the President of TurnOnGreen Inc., since January 2022 and previously served as its Chief Revenue Officer since June 2021. Mr. Charuvastra is an accomplished leader with 20 years of experience in strategic planning, sales, services, marketing and business and organizational development.

Mr. Charuvastra spent nine years at Targeted Medical Pharma Inc. serving as Vice President of Operations and as the Managing Director of this microcap biotech start-up, from 2012 to May 2021. During his tenure, he was instrumental in guiding Targeted Medical Pharma's initial public offering. Mr. Charuvastra was previously Director of Sales and Marketing at Physician Therapeutics from 2009 to 2012 and was responsible for building the sales and distribution network in the United States and abroad.

He is a graduate of University of California Los Angeles. Marcus Charuvastra as served as our President since September 6, 2022. Prior thereto, he served as the President of TurnOnGreen Inc., since January 2022 and previously served as its Chief Revenue Officer since June 2021.

Mr. Charuvastra is an accomplished leader with 20 years of experience in strategic planning, sales, services, marketing and business and organizational development. Mr. Charuvastra spent nine years at Targeted Medical Pharma Inc. serving as Vice President of Operations and as the Managing Director of this microcap biotech start-up, from 2012 to May 2021. During his tenure, he was instrumental in guiding Targeted Medical Pharma's initial public offering.

Mr. Charuvastra was previously Director of Sales and Marketing at Physician Therapeutics from 2009 to 2012 and was responsible for building the sales and distribution network in the United States and abroad. He is a graduate of University of California Los Angeles.